Interestingly, additional studies provide support for this theory; in vitro experiments show cell death induction when HER2 inhibition is combined with targeting MCL-116 and in vivo it has been shown that AZD1208 (PIM-kinase inhibitor) downregulates MCL-1 expression (among other effects) in TN breast cancer cell lines to restrict growth when used in combination with Eribulin51. Here, MCL1 is linked to breast cancer.